Table 2.
A list of representative miRNAs identified in tumor tissues that are of prognostic value in CRC patients
| miRNA | Role in CRC | Ref. |
| miR-15a/miR-16 | Their low expression levels were associated with poor disease-free survival and overall survival | [124] |
| miR-17-5p | Its high expression was associated with disease-free survival | [125] |
| miR-21 | Its high level of expression was associated with poor survival and poor therapeutic outcomes | [126] |
| miR-29a | Its elevated level of expression was associated with a longer disease-free survival in stage II CRC patients | [127] |
| miR-34a-5p | Its high expression was correlated with disease-free survival | [128] |
| miR-106a | Its downregulation was associated with shortened overall survival | [125] |
| miR-132 | Its decreased expression level was associated with poorer overall survival and occurrence of distant metastasis especially in liver | [129] |
| miR-150 | Its elevated expression level was associated with longer overall survival. While its low level of expression was associated with poor therapeutic outcome in patients treated with 5-Fluro uracil | [130] |
| miR-195 | Its low expression rate was associated with occurrence of lymph node metastasis and advanced tumor grade/stage | [131] |
| miR-199b | Increased in metastatic CRC tissue compared with non-metastatic CRC tissue. Furthermore, its low expression was associated with longer overall survival | [132] |
| miR-203 | Its elevated expression level was associated with advanced TNM staging and poorer overall survival | [130] |
| miR-320e | Its high expression was associated with poorer overall survival in stage III colon cancer patients | [133] |
| miR-429 | Its overexpression was associated with overall survival; low level of expression was associated with response to 5-Fluro uracil-based chemotherapy | [134] |
| miR-494 | Its elevated expression was associated with shorter DFS and overall survival | [135] |
| miR-625-3p | High expressions were associated with higher overall survival and enhanced response to therapy | [136] |
CRC: Colorectal cancer.